Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Shiftbio Inc. maintains 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, showing that the company's current prosecution activity is not centralized under a single administrative group or individual. This spread indicates that the company is pursuing multiple distinct lines of inquiry or different patent families within the broader biotechnology sector.
The busiest examiner, ALDARONDO, DASIA ALI, oversees 1 busiest examiner pending action. This represents a portion of the total 2 pending office actions, while the remaining action is handled by another of the 2 distinct examiners. This split across different art units suggests a diverse range of subject matter for the portfolio. For practitioners, this means that prosecution strategies may need to be tailored to the specific requirements of the assigned examiners simultaneously.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALDARONDO, DASIA ALI | 1 | 0.0% | +0.0% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18447152 | METHOD FOR INDUCING RESOLUTIVE MACROPHAGE AND USES THEROF | ALDARONDO, DASIA ALI | 17d overdue |
| 18322723 | SURFACE-ENGINEERED EXTRACELLULAR VESICLES AND THERAPEUTIC USES THEREOF | WILSON, MICHAEL C | 29d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18322723 | SURFACE-ENGINEERED EXTRACELLULAR VESICLES AND THERAPEUTIC USES THEREOF | WILSON, MICHAEL C | 29d |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18447152 | METHOD FOR INDUCING RESOLUTIVE MACROPHAGE AND USES THEROF | ALDARONDO, DASIA ALI | 1647 | §103 | Final Rejection | 17d overdue | Pending | Aug 09, 2023 |
| 18322723 | SURFACE-ENGINEERED EXTRACELLULAR VESICLES AND THERAPEUTIC USES THEREOF | WILSON, MICHAEL C | 1638 | §102§112Other | Final Rejection | 29d | Pending | May 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial